Patients' blast counts and cytogenetics on day 0 and day 25
| Patient no. . | Day 0 blast, % . | Day 25 blast, % . | Pretreatment cytogenetics (day 0) . | Cytogenetics after 1 cycle of decitabine (day 25) . |
|---|---|---|---|---|
| AML patients with blast counts > 20% or informative cytogenetics on day 25 | ||||
| 1 | 82 | 71 | 46,XX[20] | 46,XX[20] |
| 4 | 24 | 3 | 45,XY,add(2)(q33),del(5)(q13),−12,der(17)t(11;17)(q13;p12),−18, −20,+r,+mar(4)/46,sl,+21,del(21)(q22)(16)/47,sdl1,+del(5)(q13)[4]/nonclonal w/clonal abnormalities(2).ish del(5)(D5S23+,EGR1−) | 46,XY,add(2)(q33),del(5)(q13),−12,der(17)t(11;17)(q13;p12),−18, −20,+21,del(21)(q22.3),+r,+mar1[cp6]/45,sl,+add(5)(q13), −del(5)(q13),add(15)(p11.2),−16,−del(21)[cp5 one is 4n]/47,sl, +del(5)(q13)[4]/48,sl,+18,+mar2[1]/ 46,XY[4] 46,XY,add(2)(q33),del(5)(q13),−12,der(17)t(11;17)(q13;p12),−18, −20,+21,del(21)(q22.3),+r,+mar1[cp6]/45,sl,+add(5)(q13), −del(5)(q13),add(15)(p11.2),−16,−del(21)[cp5 one is 4n]/47,sl, +del(5)(q13)[4]/ 48,sl,+18,+mar2[1]/ 46,XY[4] |
| 5 | 35 | 31 | 47,XY,+13(2)/46,XY[37] | 46,XY[19]/4n[1] |
| 6 | 24 | 13 | 46,XY,t(4;21)(q33;q22)[13]/46,idem,der(3)t(3;4)(p22;q12), −4,add(8)(p12),+19,add(19)(p13.3)(cp10)/46,XY(3).ish t(4;21)(RUNX1+;RUNX1−) | 46,XY,t(4;21)(q33;q22)[1]/46,idem,der(3)t(3;4)(p22;q12), −4,add(8)(p12),+19,add(19)(p13.3)[14]/48,XY,+21,+21[3]/46,XY[2] |
| 7 | 25 | 54 | 46,XX[20] | 46,XX[28]/nonclonal[2] |
| 8 | 22 | 19 | 43,X,t(X;2)(p11.2;p11.2),del(5)(q11.2q33),−7,−12,add(16)(q11.2), −19(cp9)/43,idem,+12,dic(12;19)(p12;p13.3),−add(16), +19[2]/46,XX[7]/ nonclonal w/clonal abnormalities[2] | 44,X,t(X;2)(p11.2;p11.2),del(5)(q11.2q33),−7,der(12)del(12)(q13.1q13.3) del(12)(q24.1q24.3),dic(12;19)(p12;p13.3),−16[cp5]/44,sl,+mar[3]/46,sl, +11,+12, dic(12;19),+19[5]/46,XX[6]/nonclonal[1] |
| 14 | 39 | 31 | 46,XX[20] | 46,XX[20] |
| 15 | 50 | 44 | 46,X,idic(X)(q13)[11]/46,XX[9] | 46,X,idic(X)(q13)[6]/46,XX[14] |
| 19 | 60 | 90 | 46,XX,del(5)(q22q35)[17]/46,XX[7]/nonclonal[1] | 46,XX,del(5)(q22q35)[18]/46,XX[1]/nonclonal[1] |
| 23 | 74 | 52 | 46,XY,t(11;22)(q23;q11.2)(5)/47,sl,+mar1[5]/47,sl,+mar2[3]/48,sl, +mar3,+mar4[6]/46,XY(1).nuc ish (MLLx2)(5′ MLL sep 3′ MLLx1)(143/221)/(MLLx3)(5′ MLLsep 3′ MLLx1)(29/221) | 46,XY,t(11;22)(q23;q11.2)[1]/47,sl,+mar1[12]/47,sl,+mar2, +mar5[3]/47,sl,+ma r3,+mar4[4] |
| 24 | 82 | 45 | 46,XY[21]/nonclonal[1] | Insufficient metaphases (46,XY[8]) |
| AML patients with blast counts < 20% and uninformative cytogenetics on day 25 | ||||
| 3 | 20 | 9 | 46,XX[20] | 46,XX[20] |
| 17 | 38 | 0 | 46,XX,t(8;21)(q22;q22)[14]/45,idem,−7[6] | 46,XX[20] |
| 18 | 53 | 1 | 46,XY[29]/nonclonal[1] | 46,XY[19]/Nonclonal[1] |
| 20 | 41 | 3 | 46,XY[29]/nonclonal[1] | 46,XY[20] |
| 21 | 35 | 13 | 46,XY[20] | 46,XY[20] |
| Patient no. . | Day 0 blast, % . | Day 25 blast, % . | Pretreatment cytogenetics (day 0) . | Cytogenetics after 1 cycle of decitabine (day 25) . |
|---|---|---|---|---|
| AML patients with blast counts > 20% or informative cytogenetics on day 25 | ||||
| 1 | 82 | 71 | 46,XX[20] | 46,XX[20] |
| 4 | 24 | 3 | 45,XY,add(2)(q33),del(5)(q13),−12,der(17)t(11;17)(q13;p12),−18, −20,+r,+mar(4)/46,sl,+21,del(21)(q22)(16)/47,sdl1,+del(5)(q13)[4]/nonclonal w/clonal abnormalities(2).ish del(5)(D5S23+,EGR1−) | 46,XY,add(2)(q33),del(5)(q13),−12,der(17)t(11;17)(q13;p12),−18, −20,+21,del(21)(q22.3),+r,+mar1[cp6]/45,sl,+add(5)(q13), −del(5)(q13),add(15)(p11.2),−16,−del(21)[cp5 one is 4n]/47,sl, +del(5)(q13)[4]/48,sl,+18,+mar2[1]/ 46,XY[4] 46,XY,add(2)(q33),del(5)(q13),−12,der(17)t(11;17)(q13;p12),−18, −20,+21,del(21)(q22.3),+r,+mar1[cp6]/45,sl,+add(5)(q13), −del(5)(q13),add(15)(p11.2),−16,−del(21)[cp5 one is 4n]/47,sl, +del(5)(q13)[4]/ 48,sl,+18,+mar2[1]/ 46,XY[4] |
| 5 | 35 | 31 | 47,XY,+13(2)/46,XY[37] | 46,XY[19]/4n[1] |
| 6 | 24 | 13 | 46,XY,t(4;21)(q33;q22)[13]/46,idem,der(3)t(3;4)(p22;q12), −4,add(8)(p12),+19,add(19)(p13.3)(cp10)/46,XY(3).ish t(4;21)(RUNX1+;RUNX1−) | 46,XY,t(4;21)(q33;q22)[1]/46,idem,der(3)t(3;4)(p22;q12), −4,add(8)(p12),+19,add(19)(p13.3)[14]/48,XY,+21,+21[3]/46,XY[2] |
| 7 | 25 | 54 | 46,XX[20] | 46,XX[28]/nonclonal[2] |
| 8 | 22 | 19 | 43,X,t(X;2)(p11.2;p11.2),del(5)(q11.2q33),−7,−12,add(16)(q11.2), −19(cp9)/43,idem,+12,dic(12;19)(p12;p13.3),−add(16), +19[2]/46,XX[7]/ nonclonal w/clonal abnormalities[2] | 44,X,t(X;2)(p11.2;p11.2),del(5)(q11.2q33),−7,der(12)del(12)(q13.1q13.3) del(12)(q24.1q24.3),dic(12;19)(p12;p13.3),−16[cp5]/44,sl,+mar[3]/46,sl, +11,+12, dic(12;19),+19[5]/46,XX[6]/nonclonal[1] |
| 14 | 39 | 31 | 46,XX[20] | 46,XX[20] |
| 15 | 50 | 44 | 46,X,idic(X)(q13)[11]/46,XX[9] | 46,X,idic(X)(q13)[6]/46,XX[14] |
| 19 | 60 | 90 | 46,XX,del(5)(q22q35)[17]/46,XX[7]/nonclonal[1] | 46,XX,del(5)(q22q35)[18]/46,XX[1]/nonclonal[1] |
| 23 | 74 | 52 | 46,XY,t(11;22)(q23;q11.2)(5)/47,sl,+mar1[5]/47,sl,+mar2[3]/48,sl, +mar3,+mar4[6]/46,XY(1).nuc ish (MLLx2)(5′ MLL sep 3′ MLLx1)(143/221)/(MLLx3)(5′ MLLsep 3′ MLLx1)(29/221) | 46,XY,t(11;22)(q23;q11.2)[1]/47,sl,+mar1[12]/47,sl,+mar2, +mar5[3]/47,sl,+ma r3,+mar4[4] |
| 24 | 82 | 45 | 46,XY[21]/nonclonal[1] | Insufficient metaphases (46,XY[8]) |
| AML patients with blast counts < 20% and uninformative cytogenetics on day 25 | ||||
| 3 | 20 | 9 | 46,XX[20] | 46,XX[20] |
| 17 | 38 | 0 | 46,XX,t(8;21)(q22;q22)[14]/45,idem,−7[6] | 46,XX[20] |
| 18 | 53 | 1 | 46,XY[29]/nonclonal[1] | 46,XY[19]/Nonclonal[1] |
| 20 | 41 | 3 | 46,XY[29]/nonclonal[1] | 46,XY[20] |
| 21 | 35 | 13 | 46,XY[20] | 46,XY[20] |